26 completed, 8 terminated, 3 withdrawn, 2 unknown. 12 Phase 1, 9 Phase 3, 7 Phase 2, 7 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 12 |
| Phase 3 | 9 | Completed 5, Suspended 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 7 | Terminated 3, Withdrawn 2, Completed 1, Unknown 1 |
| Phase 4 | 7 | Completed 4, Terminated 3 |
Follow naloxegol: new trials by email Literature Review of naloxegol trials Research Report on naloxegol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Naloxegol in the Prevention of POI After Cystectomy Naloxégol oxalate, Placebo oral tablet - Bladder Cancer, Cystostomy; Complications | Phase 2 | Withdrawn | Institut Paoli-Calmettes | 2032-01-01 | 2026-10-14 | |
| The NIPA Study Naloxegol Administration to Prevent Opioids Induced Gastrointestinal Motility Disturbance in Brain Injured PAtients Naloxegol, Placebo - Brain Injuries | Phase 3 | Suspended | University Hospital, Brest | 370 | 2022-03-15 | 2026-06-16 |
| Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation Methylnaltrexone Bromide 150 mg Oral Tablet, Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1, Naloxegol 25 MG Oral Tablet - Constipation Drug Induced | Phase 4 | Completed | University of Missouri-Columbia | 15 | 2020-12-23 | 2024-09-19 |
| Effect of Naloxegol on Postoperative Ileus in Patients Undergoing Cardiac Surgery Naloxegol, inert tablet - Postoperative Ileus (Post Cardiac Surgery Constipation) | Phase 3 | Completed | CMC Ambroise Paré | 305 | 2020-10-14 | 2026-05-20 |
| Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation Naldemedine, Lubiprostone, Naloxegol - Opioid-induced Constipation | Recruiting | BioDelivery Sciences International | 34532 | 2019-01-04 | 2026-09-30 | |
| Study on Quality of Life in Advanced Cancer Patients With Opioid-induced Constipation Treated With Naloxegol Naloxegol - Opioid Use, Constipation Drug Induced | Completed | Fondazione ANT Franco Pannuti ETS | 250 | 2018-09-01 | 2022-02-28 | |
| Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC. Naloxegol - Opioid Induced Constipation | Completed | Kyowa Kirin Pharmaceutical Development Ltd | 183 | 2018-08-16 | 2024-06-17 | |
| Colonic Motor Patterns in Healthy Volunteers Naloxegol, codeine phosphate, Placebo - Opioid-Induced Constipation | Phase 4 | Completed | Universitaire Ziekenhuizen KU Leuven | 15 | 2018-06-27 | 2023-03-16 |
| Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer Naloxegol, Placebo, Laboratory Biomarker Analysis - Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | Phase 2 | Terminated | Alliance for Clinical Trials in Oncology | 50 | 2018-03-23 | 2025-07-17 |
| Naloxegol and Opioid-induced Constipation Naloxegol 25 MG, Placebo pill - Constipation, Constipation Drug Induced | Phase 2 / Phase 3 | Unknown | TriHealth Inc. | 280 | 2017-11-06 | 2022-05-05 |
| Ancillary Effects of Oral Naloxegol (Movantik) Naloxegol 25 MG, Placebo - Pain, Postoperative | Phase 4 | Completed | The Cleveland Clinic | 136 | 2017-10-01 | 2023-09-05 |
| Evaluation of the Quality of Life of Patients With Opioid-induced Constipation Under Treatment With Naloxegol Naloxegol - Opioid-induced Constipation | Completed | Kyowa Kirin Farmacéutica S.L.U. | 126 | 2017-09-21 | 2019-11-22 | |
| The Effect of Naloxegol on Refractory Constipation in the Intensive Care Unit Polyethylene glycol, naloxegol - Constipation, Critical Illness | Phase 3 | Withdrawn | Massachusetts General Hospital | 2017-05-01 | 2021-05-05 | |
| To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation Polyethylene Glycol 3350, Movantik - Opioid Induced Constipation | Phase 4 | Completed | AstraZeneca | 276 | 2017-03-02 | 2018-07-13 |
| Naloxegol for the Prevention of Constipation in Postoperative Spinal Surgery Patients MOVANTIK™ (naloxegol), Sugar Pill - Constipation | Phase 4 | Terminated | Massachusetts General Hospital | 53 | 2017-01-01 | 2019-09-10 |
| Movantik for Opioid-Related Esophageal Disorders Naloxegol, Placebo Oral Capsule - Opioid-Induced Disorders, Esophagus Disorder | Phase 2 | Terminated | Temple University | 2 | 2017-01-01 | 2018-12-24 |
| Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids Naloxegol Oral Tablet, Placebo Oral Tablet, Docusate Sodium 100 Mg oral capsule [Colace] - Constipation | Phase 4 | Terminated | Tufts Medical Center | 12 | 2017-01-01 | 2023-02-16 |
| Naloxegol for Opioid-Related Gastroparesis Naloxegol 25 MG Oral Tablet [Movantik], Placebo Oral Tablet - Gastroparesis, Opioid Use | Phase 2 | Withdrawn | Temple University | 2016-12-29 | 2020-08-27 | |
| Naloxegol Health Outcome Post Authorisation Safety Study naloxegol, non-PAMORA laxative - Opioid Induced Constipation | Terminated | Kyowa Kirin Pharmaceutical Development Ltd | 10000 | 2016-09-01 | 2024-07-23 | |
| Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation) Naloxegol, Placebo - Cancer, Constipation | Phase 4 | Terminated | Hospice of Henderson County, Inc. | 12 | 2016-09-01 | 2019-03-05 |
Showing 20 of 41. Sign in to see all of them.
Opioid-Induced Constipation (19) · Constipation (10) · Neoplasms (3) · Brain Injuries (1) · Brain Injuries, Traumatic (1) · Cancer Pain (1) · Carcinoma, Non-Small-Cell Lung (1) · Critical Illness (1) · Esophageal Diseases (1) · Gastroparesis (1) · Pain (1) · Pain, Postoperative (1) · Renal Insufficiency (1) · Subarachnoid Hemorrhage (1) · Urinary Bladder Neoplasms (1)
AstraZeneca (17) · Kyowa Kirin Pharmaceutical Development Ltd (4) · Massachusetts General Hospital (2) · Temple University (2) · Alliance for Clinical Trials in Oncology (1) · BioDelivery Sciences International (1) · CMC Ambroise Paré (1) · Fondazione ANT Franco Pannuti ETS (1) · Hospice of Henderson County, Inc. (1) · Institut Paoli-Calmettes (1) · Joseph Ma (1) · Kyowa Kirin Farmacéutica S.L.U. (1) · Michael Camilleri (1) · The Cleveland Clinic (1) · TriHealth Inc. (1)
United States (27) · United Kingdom (8) · Germany (6) · Spain (5) · Australia (3) · Belgium (3) · France (3) · Slovakia (3) · Sweden (3) · Croatia (2) · Czechia (2) · Denmark (2) · Italy (2) · Netherlands (2) · Norway (2)
Mark Sostek, MD (8) · Bo Fransson, MD (5) · Mark Sostek (5) · David Matthews, MD (2) · Thomas Marbury, MD (2) · Andrew Davies, MD (1) · Arpeat Kaviya, MBCHB, MRCP (1) · Beth Nordstrom (1) · Dave Matthews, MD (1) · Emeline Ramos (1) · Emilie Ramos, MD (1) · Enrico Ruggeri, MD (1) · Erik Garpestad, MD (1)
PMID 24896818, PMID 27342744, PMID 26535126, PMID 14739871, PMID 17955081, PMID 18721170, PMID 18924451, PMID 24238792, PMID 24883055, PMID 24904217, PMID 24945932, PMID 24946021, PMID 25112584, PMID 25164154, PMID 25802051, PMID 26150678, PMID 26312011, PMID 26582720, PMID 27486340, PMID 28059433, PMID 31058652, PMID 34830889, PMID 39988233, PMID 41681846
UL1TR000135 (1)